Table 4. Identified Unique Lipid Species and their integration with the Sphingolipid Synthesis Pathway.
| Boxed Letter | Lipid Name | Gender | State |
|---|---|---|---|
|
A (Sphingomyelinase, Sphingomyelin synthase) |
SM(d16:1/16:0) | Female/Male | Normotensive |
| SM(d16:0/22:0) | Female | Normotensive | |
| SM(d18:1/20:1) | Female/Male | Hypertensive | |
| SM(d18:0/22:0) | Female | Hypertensive | |
| SM(d16:1/20:1) | Female/Male | Hypertensive | |
| SM(d16:0/20:0) | Female | Hypertensive | |
| SM(d18:0/24:0) | Female | Hypertensive | |
| SM(d18:1/22:1) | Female | Hypertensive | |
| SM(d18:0/15:0) | Female/Male | Normotensive | |
| SM(d20:0/24:1) | Male | Normotensive | |
| SM(d16:1/16:0) | Female/Male | Hypertensive | |
| SM(d18:1/22:0) | Male | Hypertensive | |
| SM(d16:1/17:0) | Male | Hypertensive | |
| SM(d16:1/20:1) | Female/Male | Hypertensive | |
| SM(d17:1/22:0) | Male | Hypertensive | |
| SM(d18:0/14:0) | Male | Hypertensive | |
| SM(d18:0/24:1(15Z)) | Male | Hypertensive | |
| SM(d18:1/20:1) | Female/Male | Hypertensive | |
|
| |||
|
B (Ceramidase, Ceramide synthase) |
Cer(d18:0/18:1(9Z)) | Female | Normotensive |
| Cer(d18:1/18:1(9Z)) | Female | Normotensive | |
| SM(d18:0/12:0) | Female/Male | Normotensive | |
| SM(d18:0/15:0) | Female/Male | Normotensive | |
| SM(d18:0/17:0) | Female/Male | Hypertensive | |
| SM(d16:1/18:0) | Female/Male | Hypertensive | |
| SM(d16:1/20:1) | Female/Male | Hypertensive | |
| SM(d18:1/20:0) | Female | Hypertensive | |
| SM(d18:2/22:1) | Female | Hypertensive | |
| Cer(d18:0/24:1 (15Z)) | Female | Hypertensive | |
| SM(d16:1/22:1) | Female | Hypertensive | |
| SM(d18:0/20:0) | Female | Hypertensive | |
| SM(d18:0/24:0) | Female | Hypertensive | |
| SM(d18:1/15:0) | Female/Male | Hypertensive | |
| SM(d18:2/21:0) | Female | Hypertensive | |
| Cer(t18:0/26:0) | Male | Normotensive | |
| CerP(d18:1/24:0) | Male | Normotensive | |
| SM(d16:1/18:0) | Female/Male | Normotensive | |
| SM(d18:1/15:0) | Female/Male | Normotensive | |
| SM(d18:1/16:1) | Male | Normotensive | |
| SM(d18:2/15:0) | Male | Normotensive | |
| Cer(d18:1/22:0) | Male | Hypertensive | |
| SM(d16:1/20:1) | Female/Male | Hypertensive | |
| SM(d16:1/24:1) | Male | Hypertensive | |
| SM(d18:0/12:0) | Female/Male | Hypertensive | |
| SM(d18:0/18:1(9Z)) | Male | Hypertensive | |
| SM(d18:0/26:1(17Z)) | Male | Hypertensive | |
| Cer(d16:1/22:0) | Male | Hypertensive | |
| Cer(d18:0/24:1 (15Z)) | Male | Hypertensive | |
| Cer(d18:1/18:1(9Z)) | Male | Hypertensive | |
| Cer(d18:1/26:1 (17Z)) | Male | Hypertensive | |
| SM(d18:0/17:0) | Female/Male | Hypertensive | |
| SM(d18:1/25:0) | Male | Hypertensive | |
|
| |||
|
C (Sphingosine kinase, S-1-P phosphatase) |
Sphinganine-phosphate | Female | Normotensive |
| C16 Sphingosine-1-phosphate | Female | Normotensive | |
| (4E,8Z,d18:2) sphingosine | Female | Normotensive | |
| Penaresidin A | Female/Male | Hypertensive | |
| Penaresidin A | Female/Male | Hypertensive | |
Letters A, B and C indicates the location of enzyme responsible for conversion in the schematic sphingolipid synthesis pathway as depicted in Figure 1 for the identified lipid species. Lipids common to females and males have been indicated by Female/Male.